According to Precedence Research, the global plasmid DNA manufacturing market size was valued at US$ 306.4 million in 2020 and is expected to reach US$ 2.1 billion by 2030, poised to grow at a compound annual growth rate (CAGR) of 21.7% from 2021 to 2030.
The plasmid DNA manufacturing market is witnessing an upsurge due to the growing research applications in the genetic vaccination and gene therapy fields. In the present healthcare industry, the plasmid DNA play a crucial role. The plasmid DNA can be used in generation of vaccine antigens/gene therapy and for research studies. The rising number of patients seeking gene therapy is positively driving the market growth. Gene therapy is a dominating field that may offer new possible treatments for a number of diseases. The adeno-associated viral vector can be used in the treatment of Leber’s Congenital Amaurosis. Moreover, the rapid growth of the biopharmaceutical industry is significantly boosting the growth of the plasmid DNA manufacturing market. Further the growing demand for innovations in the biopharmaceutical industry is driving the demand for new manufacturing technologies for commercial production of plasmid DNA.
Rising interest in plasmid DNA manufacturing area is emphasized by the growing number of partnerships or collaborations amongst the various organizations involved in this sector. The reason behind these partnerships vary for different purposes. Collaborations have been signed for purposes including production of vector promoters and development or acquisition of manufacturing facilities and out / in licensing of plasmid DNA manufacturing technology among others.
By product type, the viral vector segment led the global plasmid DNA manufacturing market with remarkable revenue share in 2020 and is anticipated to retain its dominance throughout the forecast period. The adeno-associated viral vector is fostering the growth of this due to their applications in most of the cell-based gene therapies across the globe. Integration ability with large transgenes and simple production at high titers are some of the significant facts that help to occupy considerable share of the viral vector in the overall plasmid DNA manufacturing market.
Based on the application the market is segmented into gene therapy, DNA vaccines, immunotherapy, and others.
By application, the gene therapy segment led the global plasmid DNA manufacturing market with remarkable revenue share in 2020 and is anticipated to retain its dominance throughout the forecast period. This is attributed to the fact that gene therapy is widely used in the treatment for various genetic disorders and inherited disorders. Moreover, continuous technological advancements in developing reliable and safe treatment for different diseases is boosting the growth of this segment.
By disease, the infectious disease segment led the global plasmid DNA manufacturing market with remarkable revenue share in 2020 and is anticipated to retain its dominance throughout the forecast period. DNA plasmid is effectively used in the treatment of various infectious diseases as it provides a strong immunity through vaccine antigens and prevents pathogen infections.
On the other hand, the cancer is estimated to be the most opportunistic segment during the forecast period. The growing use of vectors for the development of cancer treatment therapies is boosting the growth of this segment significantly.
Based on the region, the North America dominated the global plasmid DNA manufacturing market in 2020, in terms of revenue and is estimated to sustain its dominance during the forecast period. The presence of numerous biopharmaceutical industry players in North America is exponentially fostering the demand for the plasmid DNA. Furthermore, the region is characterized by high disposable income, increased consumer awareness regarding gene therapies, improved healthcare infrastructure, and increased adoption of gene therapy for the treatment of various diseases. At present, around 362 therapies in clinical development has been found by the biopharmaceutical companies in US, by 2018. The increased pace of research and development in the field of plasmid DNA in US is significantly fostering the growth of the plasmid DNA manufacturing market in North America.
On the other hand, Asia Pacific is estimated to be the most opportunistic market during the forecast period. This is attributable to the increased government investments on healthcare sector and growing investments by the private players in the region to facilitate research and development activities in the field of plasmid DNA. The growing of technologically advanced methods like development of cell culture systems, expression system, and good manufacturing practices (GMP) is exponentially contributing towards the growth of the plasmid DNA manufacturing market in the Asia Pacific region. These factors make this region the fastest-growing market for the plasmid DNA.
Key Companies & Market Share Insights
The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improvedand efficient solutions. Moreover, they are also focusing on maintaining competitive pricing.
In January 2020, Helixmith&Genopis launched a new contract manufacturing unit for the production of plasmid DNA.
In December 2020, Thermo Fisher Scientific announced their plan for setting up a new GMP plasmid DNA manufacturing unit in California.
The major strategical developments are expected to drive the growth of the global plasmid DNA manufacturing market in the forthcoming years.
Some of the major players in the global plasmid DNA manufacturing market include:
Report Scope of the Plasmid DNA Manufacturing Market
|Market Size||USD 2.1 Billion by 2030|
|Growth Rate||CAR 21.7% From 2021 to 2030|
|Forecast Period||2021 to 2030|
|Largest Market||North America|
|Fastest Growing Market||Asia Pacific|
|Segments Covered||Product Type, Application Type, Disease Type, Regional Outlook|
|Companies Mentioned||VGXI, Inc., Luminous Biosciences, Akron Biotech, Cobra Biologics & Pharmaceutical Services, Plasmidfactory GmbH, Vigene Biosciences, Nature Technology Corporation, Delphi Genetics, Aldevron, JAFRAL Ltd.|
Segments Covered in the Report
No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence client